Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Liu, Y., M. Starr, H. Pang, J. Marcello, B. R. Leigh, C. P. Theuer, H. Hurwitz, and A. B. Nixon. “Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors..” J Clin Oncol 29, no. 15_suppl (May 20, 2011).

PMID
28021897
Scholars@Duke

Nixon, A. B., H. Pang, M. Starr, D. Hollis, P. N. Friedman, M. M. Bertagnolli, H. L. Kindler, R. M. Goldberg, A. P. Venook, and H. Hurwitz. “Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303..” J Clin Oncol 29, no. 15_suppl (May 20, 2011).

PMID
28022380
Scholars@Duke

Wong, Nan Soon, Nishan H. Fernando, Andrew B. Nixon, Stephanie Cushman, Mebea Aklilu, Johanna C. Bendell, Michael A. Morse, et al. “A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer..” Anticancer Research 31, no. 1 (January 2011): 255–61.

PMID
21273607
Scholars@Duke

Tailor, Tina D., Gabi Hanna, Pavel S. Yarmolenko, Matthew R. Dreher, Allison S. Betof, Andrew B. Nixon, Ivan Spasojevic, and Mark W. Dewhirst. “Effect of pazopanib on tumor microenvironment and liposome delivery..” Mol Cancer Ther 9, no. 6 (June 2010): 1798–1808. https://doi.org/10.1158/1535-7163.MCT-09-0856.

PMID
20515941
Full Text

Dugan, Elizabeth, Roxanne Truax, Kellen L. Meadows, Andrew B. Nixon, William P. Petros, Justin Favaro, Nishan H. Fernando, Michael A. Morse, Gerard C. Blobe, and Herbert I. Hurwitz. “A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors..” Anticancer Res 30, no. 4 (April 2010): 1251–56.

PMID
20530436
Scholars@Duke

Facemire, Carie S., Andrew B. Nixon, Robert Griffiths, Herbert Hurwitz, and Thomas M. Coffman. “Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression..” Hypertension 54, no. 3 (September 2009): 652–58. https://doi.org/10.1161/HYPERTENSIONAHA.109.129973.

PMID
19652084
Full Text

Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)..” J Clin Oncol 27, no. 15_suppl (May 20, 2009).

PMID
27961646
Scholars@Duke

Starodub, A., J. Jia, S. Cushman, D. Marshall, H. I. Hurwitz, and A. B. Nixon. “Dual inhibition of αV integrins and Src kinase activity in colon cancer cells..” J Clin Oncol 27, no. 15_suppl (May 20, 2009).

PMID
27964163
Scholars@Duke

Howard, L. A., K. E. Bullock, J. C. Bendell, H. E. Uronis, G. Vlahovic, G. C. Blobe, R. F. Riedel, A. B. Nixon, J. P. Gockerman, and H. I. Hurwitz. “Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors..” J Clin Oncol 27, no. 15_suppl (May 20, 2009).

PMID
27961368
Scholars@Duke

Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.

Scholars@Duke

Pages